Piramal Pharma Limited Q3FY26 Concall Decoded: 30 inspections, zero OAIs, and $100 million bets in a year management calls “muted”

---

1. Opening Hook

Muted year, they said.
Meanwhile, they announced a $35 million acquisition, doubled down on a $90 million capex plan, and promised Q4 magic.

If this is “muted,” we’d hate to see their definition of aggressive.

Inventory destocking from a large on-patent client hurt. Biopharma funding froze. Regulatory delays played villain. And yet, management is talking recovery, onshoring tailwinds, and a billion-dollar CDMO ambition still intact.

Oh, and Q4 is “historically the strongest quarter.” Of course it is.

But here’s where it gets interesting: RFPs are up sharply since October, Phase-3 pipeline remains 30+, and asset turns at overseas plants are expected to jump from sub-1x to 2–2.5x.

Read on. The optimism might be early. Or it might be timely. 😏

---

2. At a Glance

• Revenue down 3–4% YoY – “Muted year” translation: large client blinked first.
• EBITDA margin at 11% (Q3) – Cost optimization showed up; growth didn’t.
• CDMO low single-digit growth (ex-destocking) – Strip the pain, growth exists… technically.
• Consumer Health +20% YoY – E-commerce doing the heavy lifting, 50%+ growth.
• Sevoflurane US share at 47% – Market leader, now playing ROW chess carefully.
• Net debt ₹4,200 crore – Stable, but Kenalog and capex may nudge it higher.

---

3. Management’s Key Commentary

“FY ’26 has been a muted year for the Company.”
(Translation: One large client sneezed, and we caught a revenue cold.)

“U.S. biopharma funding in H2 CY25 was nearly double H1.”
(VC money is back. Let’s hope it stays longer than the last cycle. 😏)

“We saw significant improvement in RFPs since October.”
(Leads are up. Now waiting 180 days to see if they actually convert.)

“We continue to reaffirm our LRP guidance.”
(Yes, even the $1+ billion CDMO dream. Stretch acknowledged. Target retained.)

“Kenalog delivers EBITDA margins comparable to our CHG portfolio.”
(Translation: It won’t be sexy, but it’ll print steady cash.)

“Overseas asset turns are below 1 currently; we expect 2–2.5x at scale.”
(Currently underutilized. At full throttle, margin expansion party begins.)

“Q4 has historically been our strongest quarter.”
(Every company’s favorite seasonal defense line. 😌)

---

4. Numbers Decoded

Metric	Q3 FY26	Commentary
Revenue	₹2,140 Cr	-3% YoY; large client destocking dent visible
9M Revenue	₹6,117 Cr	-4% YoY; recovery narrative hinges on H2
EBITDA Margin	11%	Cost controls cushioning topline weakness
CDMO Revenue (Q3)	₹1,166 Cr	RFP momentum improving since Oct
Consumer Health Growth	+20% YoY	Power brands up ~30%;